APA (7th ed.) Citation

Bertin, L., Barberio, B., Gubbiotti, A., Bertani, L., Costa, F., Ceccarelli, L., . . . Savarino, E. V. (2024). Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease. Journal of Clinical Medicine, 13(6), 1539. https://doi.org/10.3390/jcm13061539

Chicago Style (17th ed.) Citation

Bertin, Luisa, et al. "Association Between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease." Journal of Clinical Medicine 13, no. 6 (2024): 1539. https://doi.org/10.3390/jcm13061539.

MLA (9th ed.) Citation

Bertin, Luisa, et al. "Association Between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease." Journal of Clinical Medicine, vol. 13, no. 6, 2024, p. 1539, https://doi.org/10.3390/jcm13061539.